662 results on '"Gay, Hiram"'
Search Results
102. External beam radiation therapy with or without brachytherapy boost for low PSA, high-grade prostate cancer.
103. Learning-based Cancer Treatment Outcome Prognosis using Multimodal Biomarkers
104. Treatment Outcomes for T4 Oropharyngeal Squamous Cell Carcinoma
105. Radiation Dose–Volume Effects in Radiation-Induced Rectal Injury
106. Impact of human papillomavirus on the tumor microenvironment in oropharyngeal squamous cell carcinoma
107. Weaving attention U‐net: A novel hybrid CNN and attention‐based method for organs‐at‐risk segmentation in head and neck CT images
108. A Rational Approach to Unilateral Neck RT for Head and Neck Cancers in the Era of Immunotherapy
109. Semi-supervised semantic segmentation of prostate and organs-at-risk on 3D pelvic CT images
110. Regarding the Use of PSMA PET-CT Versus Conventional Imaging for Assessing the Value of Prophylactic Whole-Pelvis Radiation for High-Risk Prostate Cancer
111. Deep-supervised adversarial learning-based classification for digital histologic images
112. Divergent viral presentation among human tumors and adjacent normal tissues
113. Isodose-based methodology for minimizing the morbidity and mortality of thoracic hypofractionated radiotherapy
114. Eliminating radiotherapy to the contralateral retropharyngeal and high level II lymph nodes in head and neck squamous cell carcinoma is safe and improves quality of life
115. Prognostic value of 18F-FDG PET metabolic parameters in oropharyngeal squamous cell carcinoma
116. Abstract 110: Colon Cancer in Patients under 50 in Guatemala: A Retrospective Comparative Cohort Study
117. Abstract CT153: Correlation ofCDKN2Agenomic alterations with tumor response to palbociclib given before chemoradiation therapy to patients with human papillomavirus-unrelated, locally advanced head and neck squamous-cell carcinoma
118. Stereotactic body radiation therapy (SBRT) versus conventionally fractionated external beam radiation therapy in unfavorable intermediate-risk prostate cancer: An inverse propensity matched analysis.
119. PRSOR07 Presentation Time: 12:30 PM
120. Association Between Surgical Margins Larger Than 1 cm and Overall Survival in Patients With Merkel Cell Carcinoma
121. PLEN02 Presentation Time: 1:30 PM
122. PRSOR01 Presentation Time: 12:00 PM
123. A novel systematic approach for cancer treatment prognosis and its applications in oropharyngeal cancer with microRNA biomarkers
124. A Radiation Oncology Departmental Policy for the 2019 Novel Coronavirus (COVID-19) Pandemic
125. A free program for calculating EUD-based NTCP and TCP in external beam radiotherapy
126. Integrated clinicopathologic and molecular risk stratification for disease recurrence in muscle-invasive bladder cancer.
127. Association of the clinical cell-cycle risk score with metastasis after radiation therapy and identification of men with prostate cancer who can forgo combined androgen deprivation therapy.
128. Association of survival and local radiotherapy to the bladder versus chemotherapy alone for patients with metastatic urothelial carcinoma (mUC).
129. Neoadjuvant versus concurrent androgen deprivation therapy plus radiotherapy for unfavorable intermediate-risk and high-risk prostate cancer with low PSA.
130. Utilization and survival outcomes between definitive versus conservative treatments among elderly men with high-risk prostate cancer.
131. Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
132. Practical considerations for quantitative clinical SPECT/CT imaging of alpha particle emitting radioisotopes
133. Outcomes of Patients With Single-Node Metastasis of Human Papillomavirus–Related Oropharyngeal Cancer Treated With Transoral Surgery
134. A novel RT-PCR method for quantification of human papillomavirus transcripts in archived tissues and its application in oropharyngeal cancer prognosis
135. A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck
136. A Microrna Expression Signature for the Prognosis of Oropharyngeal Squamous Cell Carcinoma
137. Cancer of the Major Salivary Glands
138. Radiation therapy dose de-escalation compared to standard dose radiation therapy in definitive treatment of HPV-positive oropharyngeal squamous cell carcinoma
139. A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database
140. ARPM‐net: A novel CNN‐based adversarial method with Markov random field enhancement for prostate and organs at risk segmentation in pelvic CT images
141. A prognostic gene expression signature for oropharyngeal squamous cell carcinoma
142. A MicroRNA Expression Signature as Prognostic Marker for Oropharyngeal Squamous Cell Carcinoma
143. Review: Brain Metastases in Bladder Cancer
144. Taking Guatemala From Cobalt to IMRT: A Tale of US Agency Collaboration With Academic Institutions and Industry
145. Long‐term follow‐up after radiotherapy for prostate cancer with and without rectal hydrogel spacer: a pooled prospective evaluation of bowel‐associated quality of life
146. Management of primary skin cancer during a pandemic: Multidisciplinary recommendations
147. RTOG 3506 (STEEL): A study of salvage radiotherapy with or without enzalutamide in recurrent prostate cancer following surgery.
148. Extranodal extension is a strong prognosticator in HPV‐positive oropharyngeal squamous cell carcinoma
149. A Radiation Oncology Departmental Policy for the 2019 Novel Coronavirus (COVID-19) Pandemic
150. Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase 2 Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.